Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy [clinicaltrials:NCT01649258]

Bio2RDF identifier

NCT01649258

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01649258

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01649258

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

40

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01649258 arm group 75b087e1fbc28066ea588ebb23d98cc1 [clinicaltrials_resource:NCT01649258/arm-group/75b087e1fbc28066ea588ebb23d98cc1]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:4c3cb4f1b6774aae040152e2cdb4237b

brief summary [clinicaltrials_vocabulary:brief-summary]

This clinical trial stu ...... treated with chemotherapy

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Fosaprepitant Dimeglumine and ...... Cancer Undergoing Chemotherapy

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:3d7b17e7db974d53ee04447c0808a1c7]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:5e44d780f7d18d973833482fe5d7834b]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:b773ae5059460a5c560d7bf0b494379f]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:cc1353a34df21deb1745471b605fbbe8]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:0a977548ad177eee2aeb0d56bd9c7da3]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:3ca68218c242ada0fe5f4e679730c005]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:3ea57ee2388d03f417087d5bc1b45183]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:429ce5f425c107c978262ef1dd0dab54]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:8bf2dd882c36a89c3783764780af8060]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:adaf2e9aec7a80ca90b016d26c076997]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:cc7433e542c4813f4f7644cab602c44c]

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment) Within the first 24 hours of treatment [clinicaltrials_resource:de9b5ad023dcb6ec652f8b9cd961070c]

collaborator [clinicaltrials_vocabulary:collaborator]

University of Southern California [clinicaltrials_resource:56c58f9a6dfc18340d3dca8d5c99f27b]

completion date [clinicaltrials_vocabulary:completion-date]

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

PRIMARY OBJECTIVE: ...... unacceptable toxicity.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01649258 [clinicaltrials_resource:cb6b754d130b722adb59284459597c1f]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2012-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

laboratory biomarker analysis [clinicaltrials_resource:18423d7e9eb2761ee2c8704c13a80321]

fosaprepitant dimeglumine [clinicaltrials_resource:75b4007c820eac200b7f256afabfc590]

granisetron transdermal system [clinicaltrials_resource:fc7f44f8de6220d9d09545664fd3f91b]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Granisetron [clinicaltrials_resource:0fcefe3fcdb5d201cdb2da0ee6faea9d]

Aprepitant [clinicaltrials_resource:61cb8d8764b625be6b962c21424d6aad]

Fosaprepitant [clinicaltrials_resource:8e4ccd64ec893783c0127e9e8b78c35d]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

University of Southern California [clinicaltrials_resource:56c58f9a6dfc18340d3dca8d5c99f27b]

location [clinicaltrials_vocabulary:location]

USC Norris Comprehensive Cancer Center [clinicaltrials_resource:49d87101f81d8d566120b3f205f4b06e]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01649258

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

1

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Pilot Study to Evaluate the ...... dentify Predictors of Response

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

1B-11-5

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Agustin Garcia [clinicaltrials_resource:8fec08ddf50ed4d6f29a863b9b97ee5e]

overall official [clinicaltrials_vocabulary:overall-official]

Agustin Garcia [clinicaltrials_resource:aba802abbce3c610fd45f81d84cce344]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Federal Government [clinicaltrials_resource:3e6fb85f74da576ef06d30c2ff29436f]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

NCI-2012-01170

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

University of Southern California [clinicaltrials_resource:56c58f9a6dfc18340d3dca8d5c99f27b]

start date [clinicaltrials_vocabulary:start-date]

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01649258 study design [clinicaltrials_resource:9d792ac89ae9afcccfceb679d6eeacb2]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01649258

verification date [clinicaltrials_vocabulary:verification-date]

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01649258

http://www.w3.org/2001/XMLSchema#string

title

Fosaprepitant Dimeglumine and ...... Cancer Undergoing Chemotherapy

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]